[wpv_youtube id=”VXlHo92Gpkg” width=”600″ height=”338″ suggested=”false” player=”true” title=”true”]
TORONTO, ONTARIO — ACCESSWIRE – January 18th, 2017 — The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a new stock pick, Advanced Medical Isotope (OTC: ADMD), which WBT believes has the ability to cause a massive paradigm shift in the cancer treatment space, and potentially capture a large segment of the burgeoning internal radiation therapy market. We look to follow this company as they expect to make another FDA submission later this year, which should catapult the stock if they receive the anticipated premarket approval. We also contrast and compare a few other companies in the industry.
COMPANIES MENTIONED: Advanced Medical Isotope Corporation (OTC: ADMD); Sirtex Medical Limited (ASX: SRX); Accuray Incorporated (NASDAQ: ARAY); IsoRay, Inc. (ISR: NYSE); Actinium Pharmaceuticals, Inc. (NYSE: ATNM)
For over 100 years’ oncologists (cancer doctors) have used the archaic radiation “gun” to treat cancerous tumors which is put up to a patient’s treatment area (on the outside of the body, but near where the cancer is) shooting harmful rays almost everywhere besides where its needed—on the cancerous tumor inside.
The Next Step Forward: Modern Brachytherapy
Almost as old as radiation treatment itself, brachytherapy is a type of radiation therapy whereby a radioactive substance, such as metal seeds, are placed inside the body near the treatment area, which is slightly more focused than the traditional external “gun” style method, but still very unfocused, full of side effects and many times ineffective. Only recently has modern medicine begun to perfect this method of internal treatment, with companies like Advanced Medical Isotope Corporation (OTC: ADMD) paving the way with technology driven solutions to an age old problem.
A long way from the unselective external radiation guns and implanted radioactive products, comes the Y-90 RadioGelä device, a potential breakthrough therapy in the late stages of development by Advanced Medical Isotope (OTC: ADMD)— a tiny $10 Million market cap company in the process of making a big mark in the brachytherapy industry, which is projected to reach $2.4 Billion by 2030.
The Y-90 RadioGelä device, which OTC: ADMD holds 8 patents on and trademarks in 40 different countries, is a biodegradable, ultra high intensity radioactive gel designed to be injected into any solid tumor as a liquid and then solidifies to hold the radiation in place, effectively taking over the cancerous tumor and destroying it from within. There is nothing on the market like (OTC: ADMD)’s Y-90 RadioGelä device. The devices design features make it potentially suitable for use in a broad range of solid tumors, and the company has highlighted potential opportunities in pancreatic, brain tumors and head & neck cancers. Once the product receives marketing clearance, the Company’s solid patent portfolio should secure the cash generation from this idea for many years.
Not only is the delivery system (injected directly into the tumor) of the Y-90 RadioGel™ device completely novel in a way which multiplies its potential effectiveness, but the radioactive isotope (the cancer killing agent) contained in the gel, yttrium 90, is considered to be the new standard as it has one of the highest theoretical “therapeutic doses” of cancer killing power compared to the many other products on the market. Therapeutic dose is simply the amount of cancer killing radiation that gets absorbed by the tumor versus the nearby healthy tissues.
Further to the extreme potential effectiveness of this product because of its innovative delivery system and extremely strong killing power of yttrium 90, it is actually considered to be potentially safer to the patient sparing healthy cells from being damaged—the well known fear when a loved one receives radiation—as it has a very short average radiation wavelength of 4 millimeters: meaning the radiation can only travel about 1/8 of an inch. Other methods utilize isotopes with infinite radiation path lengths, potentially hurting the entire body as its purportedly trying to heal it. Many current patients receiving radiation therapy are quarantined in a private room to protect healthcare professionals and the families of the patients from the harmful rays given off.
On top of all those benefits of OTC: ADMD’s RadioGel™, the company has stated that it feels it can offer treatments below the cost of competing therapies, which is very important considering Trump wants drugs and treatments to be competitively bid on. Also, if treated with the Y-90 RadioGelä there would not be a need for long expensive hospital stays afterwards (also convenient for the patient).
In business, and more specifically in investing, one looks for companies on the growth path with a sustainable competitive advantage, as Warren Buffet says. (OTC: ADMD) has a product like no other, that could generate the Company massive revenues at the same time as potentially helping many cancer patients in need.
At $0.17 per share (OTC: ADMD) looks to be a potential huge winner as they have hired a new CEO, completely cleaned up the balance sheet, raised additional capital to potentially submit their FDA application relatively quickly, and most importantly: have a formal plan in place to get RadioGel™ to market– as soon as possible.
Some also say the stock price is artificially low due to some historical toxic debt, but that appears to be behind them as well as it was all paid off—the blue-sky seems enormous when you see a Company like ADMD valued at $10 million and you also small biotechs gobbled up in acquisitions for $1 billion+.
The next company we will discuss appears to be about 5 years ahead of (OTC: ADMD), which further highlights their potential given the next company’s stock price hit a high this year of $40.00 (AUD).
Busting Open the Monopoly
Advanced Medical Isotope (OTC: ADMD) is taking internal radiation one step further than current competitor(s). Most brachytherapy (internal radiation) of the past relied on permanently implanting small radioactive metal seeds into a patient in a treatment area—typically for prostate or cervical cancer. This is a very old way of thinking. The type of brachytherapy device (OTC: ADMD) places a safer yet more effective isotope (Y90) inside a cancerous organ and does not dose nearby healthy tissues.
Another company looking to new methods of brachytherapy uses Selective Internal Radiation Therapy, an Australian company called Sirtex Medical Limited (ASX: SRX). Sirtex also uses the wonder-isotope Y-90 to treat liver cancer; only Sirtex uses Y-90 microspheres that are introduced to the liver tumors through its blood supply artery, some of the microspheres then become lodged within the blood capillaries of the tumors and do their killing magic. However, some of this product does travel throughout the body and doses healthy tissue. With a combined 5-year survival rate at a scary 15% (cancer.org), Sirtex has extended the lives of over 5,000 patients last year alone all over the world using its novel approach.
In researching Sirtex we uncovered what appears to be a huge opportunity in the cancer treatment space. For their year ending June 30th, 2016 Sirtex is projected to earn revenues of up to $200,000,000 (analyst estimate, Yahoo! Finance), has a long-standing 40-50% year over year growth rate and EBITDA margins greater than 30%– these numbers that would make any analyst salivate. Its important to point out Sirtex only treats liver cancer and only has a 2% global penetration.
If this company is generating $200 million yearly on one type of cancer, not being the front-line therapy for this indication, and only having a 2% market penetration, what could be the revenue potential for Advanced Medical Isotope Corporation (OTC: ADMD) be if approved?
Both ADMD and SRX have been successful in building a better mousetrap, but instead of just tweaking a design to improve upon it, ADMD has created a mousetrap that potentially catches all the mice (killing tumors) without injuring them (not spreading radiation through the body).
GET BREAKING NEWS FROM US:
To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z
Some Other Companies Doing Interesting Things in the Radiation Space
Accuray Incorporated (NASDAQ: ARAY) designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The company’s CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally.
Up 2% on the day, ARAY appears to be bouncing off its $5.00 support in what appears to be the potential formation of a double bottom reversal pattern. On the fundamental front, ARAY appears to have been piling up losses for many years, but the losses appear to be narrowing with analyst’s expectations for the year ending June 30th, 2017 at roughly at break-even.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
ATNM has been in a violent down-trend for almost 3 years—recently making a potential double bottom at around $0.86. With situations like this, Wall Street is typically waiting for a catalyst before they will jump back into the stock. If the company sees positive news in the next quarter or so, and regains a strong footing over $1.00, it could trigger a breakout to the upside. The next resistance level appears to be roughly $2.00. The company is proceeding with its phase III pivotal trial (to advance the drug to commercialization) of lomab-B which could prove to be the needed catalyst as discussed.
One of the Wealthy Biotech Trader’s editors viewed the Company’s presentation at the LD Micro Conference in December and was impressed. They’re exploring an effective way to treat cancers of the bone marrow mostly affecting the elderly, and life extension is always a topic we’re keen on.
IsoRay Medical™(NYSE: ISR) utilizes proprietary technologies to deliver novel brachytherapy approaches to clinicians. IsoRay’s Cesium-131 isotope has been used as the primary treatment for prostate cancer in over 7,000 patients. Cesium-131 is being employed as an adjuvant radiation therapy, in the management of non-small cell lung cancer, intra-cranial tumors (including meningiomas), and head & neck malignancies post-surgical resection.
On the topic of technical support and resistance levels, ISR appears to always bounce off the $0.50 level like clockwork (for the past 5 years). With only a cursory look, the company might scare Investors with average gross margins of an anemic 7.2% over the past 4 quarters, but with the sole analyst covering the stock as reported by Yahoo! Finance projecting revenue spikes of 53% and 35% for this year and next, respectively, those margins may improve. More importantly, the company is also reported by the same Analyst to potentially pass the threshold of break-even this year. This may be a situation where a company is under covered by Wall Street, and may start to shine, but Investors may need to weigh the risks and rewards on this ticker as the rate of adoption of this Company’s products by the medical establishment will weigh heavily on the final outcome.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.
GET BREAKING NEWS FROM US:
To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate.The Wealthy Biotech Trader’s parent company was compensated $50,000 as well as 100,000 restricted preferred shares by Advanced Medical Isotope Corporation. Wealthy Biotech Trader has since renewed their contract with Advance Medical Isotope for 6 months for either 40,000 restricted common shares per month or $20,000 per month, at the discretion of The Wealthy Biotech Trader’s parent company. Readers should understand that they will convert these preferred shares into common shares sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this art.
SOURCE: The Wealthy Biotech Trader